ANKH inorganic pyrophosphate transport regulator
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The ANKH gene provides instructions for making a protein that is involved in skeletal development. The ANKH protein plays a role in the development and function of cells that build bones (osteoblasts) and cells that break down bone (osteoclasts). Osteoclasts are involved in bone remodeling, a normal process in which old bone is removed and new bone is created to replace it. In addition, the ANKH protein transports a molecule called pyrophosphate out of cells to the intricate network of proteins that forms in the spaces between cells (extracellular matrix). This extracellular pyrophosphate helps regulate bone formation by preventing mineralization, the process by which minerals such as calcium and phosphorus are deposited in tissues. The ANKH protein may have other, unknown functions.
Video picks for GenesVideo library
Normal function
The ANKH gene provides instructions for making a protein that is involved in skeletal development. The ANKH protein plays a role in the development and function of cells that build bones (osteoblasts) and cells that break down bone (osteoclasts). Osteoclasts are involved in bone remodeling, a normal process in which old bone is removed and new bone is created to replace it. In addition, the ANKH protein transports a molecule called pyrophosphate out of cells to the intricate network of proteins that forms in the spaces between cells (extracellular matrix). This extracellular pyrophosphate helps regulate bone formation by preventing mineralization, the process by which minerals such as calcium and phosphorus are deposited in tissues. The ANKH protein may have other, unknown functions.
Conditions referring to this gene or chromosome
Other names
ANK
ANKH_HUMAN
ankylosis, progressive homolog (mouse)
FLJ27166
HANK
MANK
progressive ankylosis protein
SLC62A1
Patient picks for Genes

Bones, joints and muscles
Calcium pyrophosphate deposition
Calcium pyrophosphate is a substance produced in the cartilages of the joints. It can become deposited as crystals on joint tissues. This is called calcium pyrophosphate deposition. Calcium pyrophosphate deposition can cause a number of problems of which the most well known is pseudogout. This is almost identical to gout, causing attacks of pain and swelling in one or more joints. Some people develop damage to the joint, causing a type of long-term arthritis. Calcium pyrophosphate deposition may cause no symptoms and is sometimes picked up on an X-ray done for an unrelated condition. Unlike gout, there is no special treatment for pseudogout. Rest, ice packs and anti-inflammatory medicines are the main forms of treatment.
by Dr Hayley Willacy, FRCGP

Health news
Influencers are promoting dangerous peptides on social media – and regulators are struggling to keep up
Once confined to niche bodybuilding forums and hardcore gyms, unproven injectable peptides are now being openly marketed online to the average gym-goer by social media influencers – and regulators struggling to keep up. Across Instagram, TikTok or YouTube, unapproved and harmful peptide products are being promoted as shortcuts to fat loss, anti-ageing, health and recovery and muscle growth. Peptides actually occur naturally in our body. They regulate a variety of important functions, including metabolism, appetite, hormone production and tissue repair. Synthetic versions of peptides are also used in some medicines, which are legitimate and have been clinically proven. These include GLP-1s (which are used for weight loss and managing diabetes) and insulin. But a booming, parallel “grey market” now exists online for unapproved peptide compounds. These products are primarily being sold by so-called wellness brands and in influencer-led storefronts. Many of these products are marketed as cutting-edge solutions for optimising health and body enhancement. The problem is that many of these substances have not undergone full clinical safety evaluation and are not approved for human use. Many have also been found to be contaminated with other harmful ingredients. Unapproved injectable peptides therefore pose serious health risks. Some of the risks they may pose00092-0/abstract) include nausea, vomiting, abdominal pain, gastrointestinal issues, headaches and fatigue or weakness. Immune issues, as well as allergic reactions and infections have also been reported. Moreover, there’s a clear lack of rigorous human safety data. Yet these risks often aren’t disclosed by the people selling them.
by Luke Cox

COVID-19
How to reduce your risk of coronavirus on public transport
As lockdown restrictions continue to be eased across the country, more and more people are using public transport again. But for many this is an anxious experience, especially after so many months of avoiding tubes, trains and buses.
by Andrea Downey

Chest and lungs
How to avoid catching a cold on public transport
As any commuter will tell you, the threat of catching a cold is everywhere – from your sniffling co-passenger to that handrail everyone’s been touching.
by Danny Chadburn
Related patient information and medicines

Patient information leaflet
Pituitary gland disorders
This leaflet gives a brief overview of the pituitary gland and the hormones it makes. The pituitary gland is found at the base of the brain and is 'pea-sized'. The pituitary gland is an overall controller of a number of other glands in the body, overseeing the function of these organs through hormones. Some of the pituitary gland disorders.
%20and%20Matcha%20together%3F/og.png)
Patient information leaflet
Can I take Certican (Everolimus) and Matcha together?
Drinking matcha tea while taking Certican (everolimus) may increase the levels of the medication in your bloodstream. This could lead to an increased risk of side effects, such as mouth ulcers, infections, or kidney problems. Why this happens Certican is broken down in the body by a specific enzyme (CYP3A4) and a transport protein.

Patient information leaflet
Arthritis
It is a common problem and generally affects older people, although there are some rare conditions... There are lots of types of arthritis. Some give you short-term aches in the joints and then resolve completely, others can cause long-term problems and permanently affect how your joints move. This leaflet will explain a bit about how joints work.

Patient information leaflet
Medical cannabis in palliative care
Medical cannabis is sometimes considered as an additional treatment option for palliative care when standard approaches have not provided sufficient relief or have caused troublesome side effects. What is medical cannabis. Medical cannabis refers to medicines derived from the cannabis plant. In the UK, cannabis based medicinal products (CBMPs).

Patient information leaflet
Can I take Amlodipine and Apixaban together?
Alcohol... It is best to keep your alcohol intake within the recommended Using other medicines Taking multiple medicines. Our Medicines Interaction Checker helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe to take together. Simply search for your medicines to see potential interactions and what to do.

Patient information leaflet
Chondrocalcinosis
For example, it may occur in severe osteoarthritis Ost... Chondrocalcinosis increases with age and has been reported to affect about 1 in 10 people. See also the leaflet on Calcium Pyrophosphate Deposition (Pseudogout) Calcium pyrophosphate deposition. CPPD is similar to gout Gout , which is caused by excessive levels of uric acid in the body..
Further reading and references
- ANKH inorganic pyrophosphate transport regulator; MedlinePlus, National Library of Medicine.
- Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem. 2007 May 25;282(21):15872-83. doi: 10.1074/jbc.M701116200. Epub 2007 Mar 23.
- Chen IP, Luxmi R, Kanaujiya J, Hao Z, Reichenberger EJ. Craniometaphyseal Dysplasia Mutations in ANKH Negatively Affect Human Induced Pluripotent Stem Cell Differentiation into Osteoclasts. Stem Cell Reports. 2017 Nov 14;9(5):1369-1376. doi: 10.1016/j.stemcr.2017.09.016. Epub 2017 Oct 19.
- Chen IP, Wang L, Jiang X, Aguila HL, Reichenberger EJ. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD). Hum Mol Genet. 2011 Mar 1;20(5):948-61. doi: 10.1093/hmg/ddq541. Epub 2010 Dec 13.
- Gurley KA, Reimer RJ, Kingsley DM. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet. 2006 Dec;79(6):1017-29. doi: 10.1086/509881. Epub 2006 Oct 16.
- Korostishevsky M, Vistoropsky Y, Malkin I, Kobyliansky E, Livshits G. Anthropometric and bone-related biochemical factors are associated with different haplotypes of ANKH locus. Ann Hum Biol. 2008 Sep-Oct;35(5):535-46. doi: 10.1080/03014460802304588.
- Malkin I, Dahm S, Suk A, Kobyliansky E, Toliat M, Ruf N, Livshits G, Nurnberg P. Association of ANKH gene polymorphisms with radiographic hand bone size and geometry in a Chuvasha population. Bone. 2005 Feb;36(2):365-73. doi: 10.1016/j.bone.2004.09.002.
- Malkin I, Ermakov S, Kobyliansky E, Livshits G. Strong association between polymorphisms in ANKH locus and skeletal size traits. Hum Genet. 2006 Aug;120(1):42-51. doi: 10.1007/s00439-006-0173-6. Epub 2006 Apr 26.
- Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, Leschik G, Uhlmann K, Mischung C, Harrop K, Goldblatt J, Borochowitz ZU, Kotzot D, Westermann F, Mundlos S, Braun HS, Laing N, Tinschert S. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet. 2001 May;28(1):37-41. doi: 10.1038/ng0501-37.
- Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, Reginato A, Shiang R, Wright G, Netter P, Williams C, Kingsley DM. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet. 2002 Oct;71(4):933-40. doi: 10.1086/343054. Epub 2002 Sep 20.
- Reichenberger E, Chen IP. Autosomal Dominant Craniometaphyseal Dysplasia. 2007 Aug 27 [updated 2025 Aug 14]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1461/
- Reichenberger E, Tiziani V, Watanabe S, Park L, Ueki Y, Santanna C, Baur ST, Shiang R, Grange DK, Beighton P, Gardner J, Hamersma H, Sellars S, Ramesar R, Lidral AC, Sommer A, Raposo do Amaral CM, Gorlin RJ, Mulliken JB, Olsen BR. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001 Jun;68(6):1321-6. doi: 10.1086/320612. Epub 2001 Apr 16.
- Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther. 2005;7(3):R513-25. doi: 10.1186/ar1701. Epub 2005 Feb 25.
- Williams CJ. The role of ANKH in pathologic mineralization of cartilage. Curr Opin Rheumatol. 2016 Mar;28(2):145-51. doi: 10.1097/BOR.0000000000000247.
- Zaka R, Williams CJ. Genetics of chondrocalcinosis. Osteoarthritis Cartilage. 2005 Sep;13(9):745-50. doi: 10.1016/j.joca.2005.04.006.
- Zaka R, Williams CJ. Role of the progressive ankylosis gene in cartilage mineralization. Curr Opin Rheumatol. 2006 Mar;18(2):181-6. doi: 10.1097/01.bor.0000209432.36355.6e.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

